期刊文献+

真性红细胞增多症患者服用大剂量羟基脲致严重骨髓抑制伴肺部感染1例 被引量:1

Severe bone marrow suppression accompanied with pulmonary infection induced by hydroxyurea in one polycythemia vera patient
原文传递
导出
摘要 羟基脲(hydroxyurea)是一种细胞周期特异性抗肿瘤药物,通过抑制核糖核苷酸还原酶抑制细胞DNA的合成,导致细胞在S期死亡,是治疗真性红细胞增多症(polycythemia vera, PV)[1]、原发性血小板增多症[2]、β地中海贫血[3]、镰状细胞贫血[4]、慢性粒细胞白血病[5]等血液系统疾病的一线药物。PV是一种获得性源于单克隆造血干细胞增殖所致的慢性骨髓增殖性疾病.
作者 曲彩红 李晓青 黄际薇 吴小林 庄华玲 QU Cai-hong;LI Xiao-qing;HUANG Ji-wei;WU Xiao-lin;ZHUANG Hua-ling(Department of Clinical Pharmacy,the Third Affiliated Hospital of Sun Yatsen University,Guangzhou GUANGDONG 510630,China;Department of Hematology,the Third Affiliated Hospital of Sun Yatsen University,Guangzhou GUANGDONG 510630,China)
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2019年第4期254-256,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 羟基脲 真性红细胞增多症 药物相关副作用和不良反应 严重骨髓抑制 肺部感染 hydroxyurea polycythemia vera drug-related side effects and adverse reactions severe bone marrow suppression pulmonary infection
  • 相关文献

参考文献6

二级参考文献73

  • 1郭艳珍,贾竹敏,田红旗.羟基脲治疗慢性粒细胞性白血病致顽固性皮肤溃疡[J].临床荟萃,2005,20(12):706-706. 被引量:10
  • 2Prehal JF, Axelrad AA. Letter: Bone-marrow responses in poly- cythemia vera. N Engl J Med, 1974,290: 1382.
  • 3Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005,365 : 1054.
  • 4James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005,434:1144.
  • 5Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 2005,352 : 1779.
  • 6Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAN2 in polycythemia vera, essential throm bocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005,7 : 387.
  • 7Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadel-phia chromosome-negative CML, and megakaryocytic leukemia. Blood, 2005,106 : 3370.
  • 8Jones AV, KreiI S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 2005,106:2162.
  • 9James C, Ugo V, Casadevall N, et al. A JAK2 mutation in myeloproliferative disorders., pathogenesis and therapeutic and scientific prospects. Trends Mol Med, 2005,11 : 546.
  • 10Schmitt Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica, 2008,93:34.

共引文献143

同被引文献23

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部